Literature DB >> 34715356

Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective.

Shivangi Agarwal1, Samaresh Sau2, Arun K Iyer3, Anshuman Dixit4, Sushil K Kashaw5.   

Abstract

In this review, we emphasize on evolving therapeutic strategies and advances in the treatment of breast cancer (BC). This includes small-molecule inhibitors under preclinical and clinical investigation, phytoconstituents with antiproliferative potential, targeted therapies as antibodies and antibody-drug conjugates (ADCs), vaccines as immunotherapeutic agents and peptides as a novel approach inhibiting the interaction of oncogenic proteins. We provide an update of molecules under different phases of clinical investigation which aid in the identification of loopholes or shortcomings that can be overcomed with future breast cancer research.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibodies; Antibody drug conjugates; Clinical trial; Peptides; Phytopharmaceuticals; Synthetic derivatives; Vaccines

Mesh：

Substances：

Year:  2021        PMID： 34715356     DOI： 10.1016/j.drudis.2021.10.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  2 in total

1.  Development and Evaluation of 2-Amino-7-Fluorophenazine 5,10-Dioxide Polymeric Micelles as Antitumoral Agents for 4T1 Breast Cancer.

Authors:  Nicole Lecot; Belén Dávila; Carina Sánchez; Marcelo Fernández; Mercedes González; Pablo Cabral; Hugo Cerecetto; Romina Glisoni
Journal:  Polymers (Basel)       Date:  2021-12-25       Impact factor: 4.329

2.  A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects.

Authors:  Yuanyuan Sun; Heng Yang; Xiaoyan Yang; Shuang Yang; Can Guo; Honghui Chen; Chang Cui; Yuxia Xiang; Guoping Yang; Jie Huang
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.